Aminobenzoic acid for injection

Pharmacological action: This product is a procoagulant. There are various natural antagonists of plasminogen in the blood circulation, such as antiplasmin. Under normal circumstances, the activity of antifibrinolytic substances in the blood is many times higher than that of fibrinolytic substances, so fibrinolytic bleeding does not occur. However, these antagonists cannot block the activation of activators (such as urokinase, etc.) adsorbed on the fibrin network to form plasmin. Plasmin is a peptide chain endonuclease that can cleave the arginine and lysine peptide chains of fibrinogen in a neutral environment to form fibrin degradation products and cause blood clots to dissolve and bleed. Plasminogen is specifically adsorbed on fibrin through the lysine binding site in its molecular structure, and lysine can competitively inhibit this adsorption, reduce the adsorption rate of plasminogen, and thus reduce the degree of plasminogen activation to reduce bleeding. The stereo configuration of this product is similar to lysine (1,5-diaminohexanoic acid), which can competitively inhibit the adsorption of plasminogen on the fibrin network, thereby preventing its activation and protecting fibrin from being degraded by plasmin to achieve a hemostatic effect.

Chemical name: p-aminomethylbenzoic acid monohydrate. Chemical structure: Molecular formula: C8H9NO2·H2O Molecular weight: 169.18 Ingredients: The main ingredient of this product is aminomethylbenzoic acid. This product contains auxiliary materials: mannitol and hydrochloric acid.

White or off-white freeze-dried mass.

This product is mainly used for bleeding caused by excessive primary fibrinolysis, including acute and chronic, localized or systemic hyperfibrinolytic bleeding, the latter of which is common in cancer, leukemia, gynecological accidents, severe liver disease bleeding, etc.

Intravenous injection or drip, 0.1-0.3g (1-3 vials) at a time, no more than 0.6g (6 vials) per day. Or follow the doctor's advice.

Compared with 6-aminocaproic acid, this product has 5 times stronger antifibrinolytic activity and very few adverse reactions. No allergic reaction has been observed, and no thrombosis has been observed after long-term use. Occasionally, dizziness, headache, and abdominal discomfort may occur. Patients with a tendency to myocardial infarction should use it with caution.

People who are allergic to this product are prohibited from using it, and those with allergic constitutions should use it with caution.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: There is still a lack of safety research data on the use of this product in elderly patients.

1. It is incompatible with thrombolytic agents such as penicillin or urokinase; 2. The combined use of oral contraceptives, estrogen or prothrombin complex concentrates with this product may increase the risk of thrombosis.

Keep in a light-proof and airtight container.

0.1g

24 months